BD gains exclusive rights to Cygnus' GlucoWatch non-invasive monitor for $20 mil..
This article was originally published in The Gray Sheet
Executive Summary
BECTON DICKINSON PAYS $20 MIL. FOR MARKETING RIGHTS TO CYGNUS' GLUCOWATCH non-invasive blood glucose meter under an agreement announced Feb. 14. BD's $20 mil. commitment consists of an up-front equity investment and milestone payments based on progress toward bringing the device to market. In return, BD is gaining worldwide, exclusive rights to the development-stage GlucoWatch except for Japan and Korea.
You may also be interested in...
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.